Clinical Trial

4D-310 in Adults With Fabry Disease and Cardiac Involvement

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-17; most recent amendment 2025-02-19.
Status change: Active, Not Recruiting → Recruiting 2025-02-19
Status change: Recruiting → Active, Not Recruiting 2023-01-30
Trial Details
NCT Number NCT05629559
Lead Sponsor 4D Molecular Therapeutics
Conditions Fabry Disease
Enrollment 18 participants
Start Date 2022-10-16
Primary Completion 2026-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-02-21